Indivior Pharmaceuticals, Inc.
INDVFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Indivior Pharmaceuticals, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 5 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 23, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Independent insiders buying near the same time
- 2026-03-06–2026-03-13: 3 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2026-01-05–2026-01-05: 5 event(s) across 5 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-11 | Heidbreder Christian · Chief Scientific Officer | Common Stock | S — Open market or private sale | −18,586 | 38.06 | SEC filing |
| 2026-06-08 | Preblick Ryan · Chief Financial Officer | Common Stock | S — Open market or private sale | −36,000 | 37.70 | SEC filing |
| 2026-03-13 | Ryan Barbara · Director | Common Stock | P — Open market or private purchase | +8 | 31.09 | SEC filing |
| 2026-03-09 | Ryan Barbara · Director | Common Stock | P — Open market or private purchase | +31 | 32.56 | SEC filing |
| 2026-03-06 | Kingsley Stuart A · Director | Common Stock | P — Open market or private purchase | +940 | 31.87 | SEC filing |
| 2026-01-05 | Humphreys Keith · Director | Ordinary Shares | P — Open market or private purchase | +775 | 35.39 | SEC filing |
| 2026-01-05 | Wheadon David E. · Director | Ordinary Shares | P — Open market or private purchase | +1,771 | 35.39 | SEC filing |
| 2026-01-05 | NINIVAGGI DANIEL A · Director | Ordinary Shares | P — Open market or private purchase | +775 | 35.39 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-22 | Ciaffoni Joseph · Chief Executive Officer | Common Stock | M — Exercise or conversion of derivative security | +1,266,903 | SEC filing |
| 2026-06-22 | Ciaffoni Joseph · Chief Executive Officer | Performance Stock Units | M — Exercise or conversion of derivative security | −1,266,903 | SEC filing |
| 2026-06-22 | Ciaffoni Joseph · Chief Executive Officer | Common Stock | F — Payment of exercise price or tax by delivering securities | −612,549 | SEC filing |
| 2026-05-13 | Wheadon David E. · Director | Common Stock | A — Grant, award, or other acquisition | +10,430 | SEC filing |
| 2026-05-13 | NINIVAGGI DANIEL A · Director | Common Stock | A — Grant, award, or other acquisition | +6,518 | SEC filing |
| 2026-05-13 | Ryan Barbara · Director | Common Stock | A — Grant, award, or other acquisition | +6,518 | SEC filing |
| 2026-05-13 | Thompson Juliet · Director | Common Stock | A — Grant, award, or other acquisition | +6,518 | SEC filing |
| 2026-05-13 | Humphreys Keith · Director | Common Stock | A — Grant, award, or other acquisition | +6,518 | SEC filing |
Showing 8 of 28 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.